SPC249
Caplacizumab
Status:
VeittApplication date:
7.2.2019Application published:
15.2.2019Grant published:
15.11.2020
Max expiry date:
18.5.2031Next due date:
31.5.2026Medicine name:
CabliviMedicine for children:
No
Timeline
Today
7.2.2019Application
15.2.2019Publication
15.11.2020Registration
18.5.2031Expires
Marketing license
IS authorization number:
EU/1/18/1305Date:
26.9.2018
Foreign authorization number:
EU/1/18/1305Date:
31.8.2018
Owner
Name:
Ablynx N.V.Address:
Technologiepark 21, Ghent-Zwijnaarde BE
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2444424